[Effects of rosiglitazone on endothelial function in non-diabetic subjects with metabolic syndrome].
| Autor: | Bahia L; Laboratório de Pesquisas em Microcirculação, Universidade do Estado do Rio de Janeiro, RJ. lucianabahia@uol.com.br, Aguiar LG, Villela N, Bottino D, Godoy-Matos AF, Bouskela E |
|---|---|
| Jazyk: | portugalština |
| Zdroj: | Arquivos brasileiros de cardiologia [Arq Bras Cardiol] 2006 May; Vol. 86 (5), pp. 366-73. Date of Electronic Publication: 2006 May 29. |
| DOI: | 10.1590/s0066-782x2006000500007 |
| Abstrakt: | Objective: To evaluate the effects of rosiglitazone (ROSI), an insulin-sensitizer, on endothelial function and endothelial activation markers in a group of non-diabetic subjects with metabolic syndrome. Methods: A group of eighteen subjects (12 women, 6 men), mean age 41.2 +/- 9.7 and BMI 37.8 +/- 6.1 Kg/m2, was treated with rosiglitazone 8 mg/day for 12 weeks. Another group of nine healthy subjects, mean age 26.1 +/- 4.4 and BMI 21.7 +/- 1.7 Kg/m2, was studied at baseline to compare vasodilator response. Endothelial function was evaluated by venous occlusion plethysmography after intra-arterial infusions of acetylcholine (Ach) and sodium nitroprusside (SNP). The following were measured: glucose, insulin, lipids, fibrinogen, and high-sensitivity C-reactive protein (CRP). HOMA and Quicki indexes were calculated to quantify insulin resistance (IR). Results: There was an improvement in insulin resistance, as evidenced by lower HOMA-R and higher QUICKI index, as well as a decrease in CRP and fibrinogen levels. Endothelium-dependent vasodilation also improved, as evidenced by greater increment in blood flow after Ach and greater decrement in vascular resistance. No difference in endothelium-independent vasodilation was noted. Conclusion: Rosiglitazone treatment reduced insulin resistance, fibrinogen, and CRP levels and improved endothelial function in non-diabetic subjects with metabolic syndrome. These data suggest that rosiglitazone plays a role in the regulation of endothelial function in patients at high cardiovascular risk. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|